PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) reported third-quarter financial results and outlined steady progress across its upliFT-D gene therapy program, positioning the company for critical regulatory and clinical ... Read more
Mychesco - Nov 18
